Please login to the form below

Not currently logged in
Email:
Password:

Lectus wins USD 6.1m investment from Wellcome Trust

Lectus Therapeutics wins a USD 6.1m capital award from the Wellcome Trust to fund a programme to identify new classes of selective potassium channel modulator drug candidates to treat multiple sclerosis

Lectus Therapeutics, a UK-based drug discovery and development company, has received a GBP 3m (USD 6.1m) investment capital award from the Wellcome Trust to fund a programme to identify new classes of selective potassium channel modulator drug candidates to treat multiple sclerosis (MS).

The funding derives from the Wellcome Trust's 'Seeding Drug Discovery Initiative', and will allow Lectus to leverage its proprietary LEPTICS (Leveraged Enabling Proteomics Technology for Ion Channel Screening) technology to identify novel drug candidates for MS.

The compounds will target a novel, first-in-class mechanism of action and are anticipated to address some of the problems associated with existing drugs on the market and in development for the disorder. 

Per the agreement, the Wellcome Trust will retain the option to fund subsequent preclinical and clinical development of compounds identified through the alliance.

Dr Roland Kozlowski, CEO of Lectus, said: "The partnership provides both significant endorsement of the company's scientific and corporate strategies and aligns the company's strength in discovery and development with the charitable objectives of the Wellcome Trust."

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, added: "The funding will support an innovative drug discovery programme in an area of unmet medical need and validate the approach for identifying next-generation ion channel modulators for further disease indications."

According to a Research and Markets' report, the 2006 global MS market is estimated to be worth USD 4.9bn, with an annual growth rate of 8.9 per cent. It is the fifth largest segment of the CNS market. The MS market is currently dominated by six treatments: Avonex (Biogen), Betaseron/Betaferon (Schering), Copaxone (Teva), Novatrone (Schering), Rebif (Serono/ Pfizer) and Tysabri (Biogen/ Elan).

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics